This is a type of lung cancer that grows very quickly and is very aggressive. It's a serious form of cancer that needs to be treated carefully. It's often found in people who smoke.
Every report comes from a Lived member, sent anonymously.
Have you tried Carboplatin for Small Cell Lung Cancer?
Small cell lung cancer is a fast-growing type of lung cancer. Its name comes from how the cells look under a microscope: small and tightly packed. An older name for the most common form is oat cell cancer. It makes up roughly 10 to 15 out of every 100 lung cancers. The more common type, non-small cell lung cancer, grows and is treated differently, so knowing which type someone has shapes almost every decision that follows. What sets small cell lung cancer apart is its speed. It tends to spread early, and in most people it has already reached other parts of the body by the time it is found. The same fast growth makes it respond well to chemotherapy and radiation at first, often shrinking a great deal, but for most people it comes back at some point. Common symptoms include a cough that doesn't go away or gets worse, shortness of breath, chest pain, coughing up blood, hoarseness, tiredness and weight loss without trying. This cancer is also more likely than other lung cancers to cause paraneoplastic syndromes: problems in distant parts of the body that happen even though the cancer has not spread there. Some tumors release hormone-like substances. For example, a tumor that makes antidiuretic hormone (the hormone that tells the kidneys to hold onto water) can lower the sodium level in the blood, causing tiredness, nausea, muscle cramps or confusion. In other cases the immune system, reacting to the tumor, attacks nerves, causing weakness that makes it hard to rise from a chair (Lambert-Eaton syndrome) or problems with balance. These effects are sometimes the first sign of the cancer.
Smoking is the major risk factor for small cell lung cancer. Cigarettes, pipes and cigars all raise the risk, and it climbs the earlier a person starts, the more they smoke each day and the more years they smoke. Quitting lowers the risk compared with continuing, although it stays higher than for someone who never smoked. Other contributors include secondhand smoke, radon gas in a home or workplace, on-the-job exposure to substances such as asbestos, arsenic, chromium, nickel, soot or tar, past radiation therapy to the chest or breast, air pollution and a family history of lung cancer. Risk also rises with age. These are risk factors, not certain causes: many people with them never develop lung cancer, and some people with no known risk factor do.
A lingering cough, breathlessness or another symptom usually leads first to a chest x-ray or a CT (computed tomography) scan, a detailed x-ray that builds cross-sectional pictures of the chest. Imaging can show a mass or enlarged lymph nodes, but it cannot show what kind of cancer is present. That takes a biopsy: a sample of tissue or fluid removed with a thin needle guided by a scan, through a bronchoscope (a thin lighted tube passed through the nose or mouth into the airways), or from lymph nodes in the middle of the chest. A pathologist examines the cells under a microscope and uses special stains to tell small cell lung cancer apart from other types. Because this cancer spreads early, the next step is staging, which means finding out where it has gone. This usually involves a PET-CT scan, which uses a small amount of radioactive sugar that cancer cells take up more readily than normal tissue, and an MRI (magnetic resonance imaging) scan of the brain. Blood tests check overall health and organ function. Small cell lung cancer is usually described in two stages. Limited stage means the cancer is in one lung and may have reached the area between the lungs or lymph nodes above the collarbone. Extensive stage means it has spread farther, for example to the other lung, the liver, bones or brain. About two in three people already have extensive-stage disease when they are diagnosed. Because the stage drives treatment, some people seek a second opinion on the biopsy and scans before starting.
Treatment depends mainly on the stage and a person's overall health, and the goal differs between stages. For limited stage, treatment aims for long-term control and, for some people, cure. For extensive stage, cure is unlikely, and treatment aims to shrink the cancer, ease symptoms and help people live longer. For limited stage, people who are well enough usually receive chemotherapy and radiation to the chest at the same time (concurrent chemoradiation). The chemotherapy is typically etoposide combined with a platinum drug, cisplatin or carboplatin. Giving both together helps people live longer and improves the chance of cure compared with giving one treatment or one after the other, but it causes more side effects. If the cancer has not grown after chemoradiation, durvalumab (Imfinzi) may follow; it is an immunotherapy drug, meaning it helps the immune system recognize and attack cancer cells. Surgery is an option for very few people, those with one small tumor and no spread to lymph nodes, and it is followed by chemotherapy. For extensive stage, the usual first treatment is etoposide with cisplatin or carboplatin, combined with an immunotherapy drug, either atezolizumab (Tecentriq) or durvalumab (Imfinzi). After several months the immunotherapy can continue on its own as maintenance; atezolizumab may be paired with lurbinectedin (Zepzelca), another chemotherapy drug. Tumors shrink significantly in most people, and adding immunotherapy helps some live longer. Immunotherapy can occasionally cause the immune system to inflame healthy organs, which is why blood tests and symptom checks continue throughout. Because about half of people with this cancer would otherwise develop spread to the brain, people whose cancer responds well may be offered low-dose radiation to the head, called prophylactic cranial irradiation. It lowers that risk but can cause tiredness, headaches or problems with memory and thinking, so it is a decision worth weighing with the care team. If the cancer grows or returns, the next option depends on how long it stayed in remission and on past treatment. Choices include other chemotherapy drugs such as topotecan or lurbinectedin, and tarlatamab (Imdelltra), a newer immunotherapy that links the body's T cells (a type of immune cell) to a protein called DLL3 on the cancer cells. Tarlatamab can cause cytokine release syndrome, a body-wide immune reaction with fever and low blood pressure, as well as confusion or other nervous system effects, so the first doses are given in increasing steps with close monitoring. Clinical trials are a reasonable option at every stage. Radiation, laser treatment or a stent (a small tube that props an airway open) can also relieve symptoms such as bone pain, bleeding or breathing trouble from a blocked airway. For people who smoke, stopping is part of treatment: in limited-stage disease, continuing to smoke may shorten survival.
Initial chemotherapy is usually given in cycles of 3 or 4 weeks, typically 4 to 6 cycles, with treatment days followed by recovery time. Chest radiation, when used, is often given once or twice a day, five days a week, for 3 to 7 weeks. Common chemotherapy effects include tiredness, nausea, hair loss, mouth sores and a higher chance of infection or bruising because blood counts drop between doses. Cisplatin and carboplatin can cause numbness or tingling in the hands and feet. Most of these effects ease after treatment, and medicines can prevent or reduce many of them. The outlook depends heavily on stage. Among people diagnosed between 2012 and 2018, about 34 out of 100 whose cancer had not spread outside the lung were alive five years later, compared with about 4 out of 100 whose cancer had spread to distant organs. Those figures predate current immunotherapy, cannot predict any one person's course and apply only to the stage at diagnosis. Even after a strong response, small cell lung cancer comes back in most people, often within the first two years, so regular scans and checkups continue after treatment ends. Palliative care, which focuses on comfort, breathing, pain, appetite and emotional support, can work alongside cancer treatment from the start rather than only at the end. Planning early, while a person feels well enough to take part, helps keep decisions about treatment goals, work and care in their own hands.
See a doctor if you have a cough that doesn't go away or gets worse, are coughing up blood, become short of breath, or lose weight without trying, especially if you smoke or used to. During treatment, call your cancer care team right away for a fever of 100.5°F (38°C) or higher or shaking chills, since infections can become serious quickly when blood counts are low. Also call promptly for new confusion, nausea with muscle cramps or weakness (which can signal low sodium), or gradual swelling of the face or neck. Get emergency care for sudden swelling of the face, neck or arms with trouble breathing, which can mean the tumor is pressing on the large vein that drains the head and arms. Call 911 for a seizure.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Small Cell Lung Cancer is like, what's helped you, or ask the community a question.